You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
| Title |
Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
|
|---|---|
| Published in |
Biomarker Research, September 2014
|
| DOI | 10.1186/2050-7771-2-16 |
| Pubmed ID | |
| Authors |
Francine Foss, Bertrand Coiffier, Steven Horwitz, Barbara Pro, H Miles Prince, Lubomir Sokol, Matthew Greenwood, Adam Lerner, Dolores Caballero, Eugeniusz Baran, Ellen Kim, Jean Nichols, Barbara Balser, Julie Wolfson, Sean Whittaker |
| Abstract |
Histone deacetylase inhibitor romidepsin has demonstrated durable clinical responses and tolerability in patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma (PTCL, CTCL). Selection of novel drug therapies for patients with relapsed/refractory aggressive lymphoma requires not only considerations regarding efficacy but also careful evaluation of toxicities as well as overall clinical benefit. The purpose of this analysis was to examine common adverse events (AEs) reported in pivotal trials of romidepsin in relapsed/refractory PTCL or CTCL and to more clearly define the overall AE profile in these populations. |
Mendeley readers
The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 7% |
| Unknown | 14 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 3 | 20% |
| Student > Master | 3 | 20% |
| Student > Bachelor | 2 | 13% |
| Other | 1 | 7% |
| Student > Doctoral Student | 1 | 7% |
| Other | 1 | 7% |
| Unknown | 4 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 27% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 20% |
| Agricultural and Biological Sciences | 2 | 13% |
| Biochemistry, Genetics and Molecular Biology | 1 | 7% |
| Economics, Econometrics and Finance | 1 | 7% |
| Other | 1 | 7% |
| Unknown | 3 | 20% |